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                                                      Foreword 
 
The HSE National Drug Treatment Centre and the Drug Analysis Laboratory continues 
to provide a nationwide service to the HSE Addiction Services, hospitals, General 
Practitioners, voluntary organisations, Department of Education (juvenile detention 
centres), the Probation Service, the Courts Service, the Medical Council, An Bord 
Altranais and various occupational health departments.  
 
Some of the topics which have been updated in this fifth edition of our Laboratory 
Service Users Guide include: 
 
 Testing for ‘Headshop’ products (New Psychoactive Substances) 
 Cross reactivity information on Oral Fluid 
 Information on ISO/IEC 17025: accreditation 
 Measurement Uncertainty information 
 Tests available 
 
Generally, we have tried to make the guide as clear and concise as possible. 
 
I welcome the 5
th
 publication of this user guide and I commend the hard work of our 
laboratory team for its compilation and distribution. 
 
 
 
Sheila Heffernan 
National Lead, Performance Monitoring & Quality Assurance (Addiction Services) and 
Head of the National Drug Treatment Centre 
May 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © The HSE National Drug Treatment Centre. 
This document shall not be reproduced except in full without the written approval of the laboratory of 
The HSE National Drug Treatment Centre. 
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Introduction 
 
This toxicology laboratory guide has been written for medical, nursing and support 
staffs who avail of The HSE Drug Treatment Centre (HSE-NDTC) drug analysis 
service. It provides general information on how to access this service and details the 
range of tests available. 
 
The Drug Analysis Laboratory is the leading centre for drugs of misuse testing in 
Ireland. It provides a national drug analysis service to the HSE Addiction Services, 
general practitioners, hospitals (general, psychiatric and maternity), juvenile detention 
centres, voluntary organizations, the Dublin Drug Court and the Probation Services. 
 
The laboratory has a full-time staff of twelve, including biochemists, laboratory aides 
and an administrative assistant. 
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General Information 
 
 
Address:  HSE National Drug Treatment Centre, 
 
McCarthy Centre,  
 
30-31 Pearse Street,  
 
Dublin 2. 
 
 
 
 
Reception/General Enquiries: 6488600 / 6488601 
 
 
 
Chief Executive Officer: Ms. Sheila Heffernan  
Clinical Director (Acting): Dr. Eamonn Keenan 
Principal Biochemist: Ms. Siobhan Stokes  
 
 
Opening Hours of Laboratory: Mon – Fri 
 
                                                                         8.45am - 5.00pm 
 
Laboratory Tel. Nos.: 
 
Enquiries:  01-6488645 
 
Principal Biochemist:  01-6488644 
 
Laboratory e-mail:     lab@dtcb.ie 
 
 
 
Website: www.addictionireland.ie 
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Samples for Drug Analysis 
 
Samples for drug testing include urine, blood, hair and oral fluid. 
 
Table 1:  Drug detection times in biological matrices 
 
Urine 
Urine is the most commonly used specimen due to its ease of collection and long 
window of detection (drugs can be detected for a number of days, and in some cases, 
weeks, after last use). It is the universally preferred sample for testing for the presence or 
absence of drugs. However, urine is unsuitable for determining drug levels due to the 
many factors which influence the composition and concentration of urine.  
 
Blood 
Blood is more suitable than urine for determining drug levels however it is more difficult 
to collect especially from intravenous drug users and drug levels are low compared to 
levels found in urine. The time during which the drug can be detected after use is in 
the order of hours, as opposed to days.  
 
Oral fluid (Saliva) 
Sampling may be time consuming and the volume of oral fluid is small. Drug levels in oral 
fluid are low compared to levels found in urine. Testing of oral fluid is not as well 
developed as urine testing and it has a short window of detection.  
 
Hair 
Hair can demonstrate a historical record of drug use. However, the sampling must be 
carried out according to a detailed protocol and the analysis is very time consuming and 
highly specialized. There can be issues such as external contamination of the hair. 
Hair is not routinely tested by this laboratory. 
 
 
 
Consent 
 
The HSE NDTC Drug Analysis Laboratory does not take responsibility for obtaining 
“consent to test” for samples received for drug testing. 
Consent should be obtained by the doctor or organisation requesting the test, prior to 
sending samples to the laboratory. If the client is under 18 years old, consent should 
be obtained from a parent or guardian. 
 
 
 
 
Sample type Detection time range Drug use detected 
Oral fluid 0-48 hours Acute, under the influence 
Blood 0-48 hours Acute, under the influence 
Urine Days - weeks Recent 
Hair Use over extended time Chronic/ Forensic 
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Packaging and Transport 
 
The laboratory will only accept samples packaged according United Nations (UN) 
regulations. Under these regulations samples are divided into two groups: 
1)  Diagnostic: a specimen collected for the purpose of diagnosis. 
2) Infectious: a specimen containing a viable microorganism that is known, or 
reasonably believed, to cause disease. 
 
UN approved packaging consists of a triple packaging system: 
• Primary receptacle – the urine bottle. This must be leak-proof, clearly labeled 
and wrapped in enough absorbent material to absorb all fluid in case of 
breakage. 
• Secondary receptacle - used to enclose the primary receptacle. This must be 
durable and leak-proof. Several primary receptacles may be placed in one 
secondary receptacle. Sufficient additional absorbent material must be used to 
cushion multiple primary receptacles. 
• Outer packaging – the secondary receptacle is placed in an outer package 
which protects it and the contents from outside influences such as physical 
damage and / or water while in transit. 
 
Supply 
Packaging is available commercially (Please contact the laboratory directly if you 
require further information). 
 
NOTE: It is the responsibility of the sender   to   ensure   the   correct   designation,   
packaging, labeling and documentation of all specimens. 
 
Sample Collection 
The procedure for sample collection is detailed in Table 2 below. 
 
Table 2:  Sample collection  
Sample Type Collection Details 
Urine  Use clean plastic container without preservative. 
 20 - 30mls where possible. 
 Supervised to ensure sample is not adulterated 
 Where collection bottle with temperature strip is used temperature of 
urine should be between 34-39
0
C when freshly voided 
 Sample should be stored in a cool, dry place (preferably refrigerated) 
pending dispatch to the laboratory 
 Sample should be dispatched  to Laboratory as soon as possible 
Oral Fluid  Use Quantisal collection device. 
 Observe donor 10-15mins without food or drink prior to collection. 
 Supervise collection (approx. 5 mins). 
Blood (Serum 
Methadone only) 
 Serum Red Cap Tube 
 10 mls where possible 
Hair  Details on hair collection can be obtained from Laboratory  Customer 
Services 
NOTE: Standard precautions and procedures should be followed when sampling. 
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Sample Label Information 
 
The following information must be included on the sample container and any request 
form when submitting a sample for analysis: 
• Patient’s full name*    • Name of Doctor 
• Date of birth*      • DAIS code (where applicable) 
• Name of clinic or hospital*    • Sample type 
• Date of sample collection* 
*Mandatory  
Failure to include the above information hinders the processing of a sample. 
 
 
Non-Compliant Samples 
 
Non-compliant samples are samples which do not demonstrate the mandatory 
information required to identify a particular sample, i.e. full name, date of birth, 
sample date and location from which the sample was sent.  
 
Samples missing any of the aforementioned data cannot be analysed. The laboratory 
will make every effort to obtain the correct sample identification in order to proceed with 
analysis. 
 
Leaking samples are non-compliant samples. Leaking samples will not be analysed 
and the sample will be disposed of immediately. 
 
Notification of non-compliances will be sent to the sender by means of a comment on 
report or a non-compliance form detailing the nature of the non-compliance. . 
 
 
 
 
Request Forms 
 
Request forms for routine screening are available on our website 
www.addictionireland.ie.  
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Range of Testing 
 
Testing is divided into several categories including: 
 Testing for adulteration  
 Routine urine screening 
 Non-routine urine screening  
 Confirmatory analysis  
 Oral fluid screening  
 Serum Methadone levels.  
See details in the Table 3 below. (See page 5) 
 
Testing for adulterants   
Adulteration testing refers to tests carried out to determine whether a sample is 
genuine or if it has been tampered with. Methods of urine adulteration include dilution 
with, addition of, or substitution by, a drug-free substance or solution.  
 
Dilution is probably the most common method of adulteration used by drug users to 
evade detection of misuse. Creatinine levels in urine can indicate the extent of this 
dilution, therefore all samples received for analysis are tested for creatinine.  
 
‘Normal’ urine should have a Creatinine concentration in the range 80-200mg/dL.  
 
‘Dilute’ urine is indicated by a Creatinine reading of less than 20mg/dL. 
         
‘Abnormal’ urine is indicated by a Creatinine reading of <2mg/dL.  
No other test results will be reported on these samples 
 
Abnormal pH readings will indicate tampering of a sample by the addition of or 
substitution by, another substance or liquid. 
 
Subcontracted testing 
If a request is received for a test which is not normally performed, the laboratory may 
subcontract testing as a service to the customer, if required. In this instance, the 
laboratory will endeavor to subcontract the testing request to a competent external 
laboratory which complies with ISO/IEC 17025 or equivalent. The Laboratory does not 
subcontract tests within the scope of its accreditation. 
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Table 3: Range of Testing 
Sample type Test Type Method Test Window of 
Detection 
Turnaround 
Times 
Urine Routine 
Screen 
IA Opiate Class* 3-10 days 48 hours 
6-AM* 24 hours 
Benzodiazepine Class* 2-28 days 
EDDP* unknown 
Cannabis class* 2-28 days 
Cocaine* 2-4 days 
Amphetamine Class* 1-2 days 
Enzymatic Alcohol* 1-2 days 
Chemical Creatinine* n/a 
Non-
Routine 
Enzymatic Pregnancy n/a 
Chemical pH* n/a 
Glucose n/a 
IA EtG – Alcohol marker* 1-4 days 
Buprenorphine* 2-4 days  
Confirm LC-MS 
 
Opiate Identification 3-10 days 10 days 
 Zopiclone* Unknown 
‘Headshop’ products 
(psychoactive substances) 
Unknown 
THC-COOH* (Cannabis 
metabolite) 
2-28 days 
LC-MS Benzodiazepine 
identification 
2-28 days 
Oral Fluid Screen IA Opiate Class*  48 hours 
6-AM*  
Benzodiazepine Class*  
Methadone*  
Cannabis class*  
Cocaine*  
Amphetamine*   
Methamphetamine*  
Blood Screen IA Methadone levels n/a Contact Lab 
 
** Please Note: Turnaround time is measured from time of receipt of sample at the laboratory 
* These tests are accredited under ISO/IEC 17025. See Accreditation 
Abbreviations: 
6-AM: 6-acetylmorphine, primary metabolite of heroin;         EtG – Ethyl Glucuronide (Alcohol biomarker) 
EDDP:  2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine, primary metabolite of methadone 
LC-MS: Liquid Chromatography Mass Spectrometry; IA:  Immunoassay; Screen: Screening Test 
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Routine Screening Analysis 
 
The majority of drug testing performed by the laboratory falls into this category. Routine screening is 
carried out by immunoassay, enzyme assay or chemical assay. These are rapid methods used for 
screening drugs of misuse. Tests included in routine screen are detailed in table 3 above. 
 
Immunoassay is a qualitative method which indicates only the presence or absence of a drug/drug class 
in a sample. 
 
 Each test by immunoassay has a defined cut-off level, above which the test is deemed positive indicating 
that the presence of a drug/drug class was detected above the cut-off level.  
If a test result falls below the cut-off level, the result is deemed negative indicating that the drug/drug class 
was not detected above the cut-off.  
Cut- off levels is detailed on every test report. 
 
With the exception of alcohol, the current format used does not give any information about the level or 
concentration of the drug present. 
 
It should be noted that all analytical results are subject to Uncertainty of Measurement (UOM), *see 
section on Uncertainty of Measurement (page 11). The performance of qualitative test results around the 
cut-off concentration is routinely monitored by the use of quality controls which are run with every batch of 
samples. Clinical consideration and judgment should be applied to all immunoassay test results. 
Confirmatory analysis may be requested for a positive drug screening result if required. (See page 8) 
 
 
 
‘True and ‘False’ Positives 
 
Care should be taken when interpreting immunoassay screening results, as some over the counter drugs 
will give ‘true’ positive results. An example of this is Solpadeine®   which will give a positive opiate result 
because it contains codeine, which is also classified as an opiate type drug.  
Some drugs and medications can also produce ‘ false’ positive results when tested using 
immunoassay, due to cross reactivity and further confirmatory analysis may be necessary. This cross 
reactivity occurs most commonly with opiate and amphetamine drug classes.  
A study carried out in our laboratory showed that for the CEDIA® Amphetamine/Ecstasy assay, cross 
reaction was occurring with other compounds particularly new psychoactive substances such as 
cathinones (‘Headshop’ Drugs/Bath Salts/Legal Highs).  If you have any queries about an amphetamine 
positive result please contact the laboratory. Confirmatory analysis can be carried out on request. 
Benzodiazepines,   cannabis,   cocaine   and   EDDP immunoassay tests are relatively specific and 
rarely produce false positive results.  See Appendix 1 for table of urine kits cross-reactivities.  
Because of cross-reactivity, screening results by immunoassay alone are not legally defensible and further 
confirmation of the test result is required depending on the purpose of the testing.  
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Therapeutic drug monitoring of Methadone 
 
Therapeutic drug monitoring of methadone is performed to identify rapid Methadone metabolisers and can 
help with titrating Methadone dosages, provided other factors are considered when interpreting the 
result, e.g. sex, weight, time of dose, time of sampling etc. ( It is always important to treat the patient, not 
the level). 
 
Blood samples should only be submitted for serum Methadone level testing if the following criteria have 
been adhered to: 
 
CRITERIA 
•   A minimum of 3 days supervised Methadone consumption prior to the day of blood collection. 
•   The time of dosing on each day should be the same +/- 30 minutes. 
•   The blood sample must be taken immediately before the next dose on day 4. 
•   The time must be the same as the previous 3 days +/- 30 minutes. 
•   Samples must be collected into a serum tube. 
•   The sample must be accompanied by a request form/ letter which includes time of dose on previous 
day, time of dose on day of sampling and time of blood collection. 
 
Failure to adhere to these guidelines will result in unreliable data and defeat the purpose of carrying out 
the procedure. 
 
Therapeutic levels of Methadone: 
‘With chronic administration of 100-200 mg daily oral doses to tolerant subjects, the plasma concentration 
peaked at 4 hours, with an average value of 0.83ug/ml (range, 0.57 -1.06) and declined to 0.46mg/L 
(range, 0.28-0.79) 24 hours after last dose (average plasma half life of 25 hours).’  
‘It has been estimated that trough plasma methadone levels should be at least 0.05 - 0.10 mg/L to prevent 
withdrawal systems in narcotic maintenance patients (i.e. 50-100ng/ml)’. 
[Baselt 2004, Disposition of Toxic Drugs and Chemicals in man, 6
th
 edition, p. 642 – 643] 
 
Non-Routine testing 
 
Non-routine tests include 6-Acetylmorphine (6-AM) the primary metabolite of Heroin, Zopiclone, 
Buprenorphine, ‘Headshop’ drug analysis (New Psychoactive substances, see Appendix 4), pregnancy 
testing, pH, glucose and Ethyl Glucuronide (EtG). 
These tests are carried out on request only. 
The full range of analyses available is indicated in Table 3 (page 5). 
 
New Tests 
Ethyl Glucuronide (EtG)  
EtG is a direct metabolite of ethanol and can be detected several days after the elimination of alcohol from 
the body thus increasing the window of detection of alcohol use.   
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Confirmatory Analysis 
 
Confirmatory analysis is carried out using gas chromatography mass spectrometry (GC-MS) and liquid 
chromatography mass spectrometry (LC-MS).  
 
Confirmatory test results are legally defensible provided the sample integrity can be proven (see Sample 
Collection and Chain of Custody information). 
 
All confirmatory testing (with the exception of chain of custody samples) should be specifically requested 
in writing by a doctor.  
See Table 3 (page 5) and Appendices 2 & 3 for further details. 
 
 
 
 
Oral Fluid testing 
 
Oral Fluid tests include Opiates, Benzodiazepines, Methadone, Amphetamine, Methamphetamine, 
Cocaine, Cannabis and 6-Acetylmorphine (the primary metabolite of Heroin). These tests are carried out 
on request only.  Currently the laboratory recommend using Quantisal
®
 collection devices (product code 
QS-0025) available from Alere Toxicology PLC (Concateno) ++44-1235861483. 
 
Depending on the drug used, dose, and route of administration, a drug may be detected in oral fluid in less 
than one hour after use and remain detectable up to 48 hours after last use. 
Substances such as food, beverages, over-the-counter medication, and mouthwash can affect the oral 
fluid drug test results. For this reason, before collection of saliva or oral fluid, the collector should observe 
the donor for a 10-15 min period in which the donor should not smoke, consume food or drink. 
The full range of analyses available is indicated in Table 3 (page 5) above. 
 
 
 
 
Subcontracted testing 
 
Tests are subcontracted only on request by the customer. 
 
Testing which may be subcontracted include:- 
 Hair testing for drugs 
 Testing for Carbohydrate Deficient Transferrin (CDT), a metabolite of alcohol which indicates 
recent consumption of alcohol even when all of the alcohol has been metabolized. 
 Confirmatory analysis for drugs not routinely analysed in the HSE-NDTC Laboratory. 
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Chain of Custody 
 
In order for test results to be defensible in a court of law or professional hearing, chain of 
custody procedures must be followed.   
 
Chain of custody involves fully documenting who donated, collected and handled the sample thereafter. 
The HSE-NDTC laboratory can provide information on chain of custody collection kits and sampling 
procedures. All positive immunoassay screening test results must be confirmed by a second analysis 
using a confirmatory analytical method.  
 
For further information please contact Laboratory Customer Services. 
 
 
 
Storage and Retention of Samples 
 
Samples should be sent to the laboratory at the earliest opportunity. If there is any delay, it is 
recommended that samples are stored in a refrigerator at 4ºC or in a cool dark place, if refrigeration is not 
available. Post analysis, the laboratory will retain samples for 14 days in refrigerated conditions, after 
which they will be disposed of safely. Should further testing be required outside of this period (e.g. for 
Zopiclone analysis) samples will be stored in refrigerated conditions until testing is complete. 
        
Unless otherwise agreed, all Chain of Custody samples will be frozen and retained for 36 months and 
all Probation samples will be frozen and retained for 12 months post analysis. 
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Reporting of Results 
 
The front page of each report details the customer name and address, date on which each report is 
generated and scope of INAB accreditation (for accredited tests only). 
 
Each patient is identified by name, date of birth, clinic code and chart number.  
 
Each sample is identified by a unique barcode and sample date.    
   
If a drug/drug class is detected in a sample, the result will appear as a "+" (positive), indicating the 
presence of the drug.  
 
When no drug/drug class has been detected, it will be reported as a "-" (negative), indicating that the 
drug/drug class has not been detected above the cut-off level or    concentration.  
 
A blank space indicates that no test was carried out. Screening results will be available within 24-48 
hours of receipt of samples in the laboratory. Confirmatory testing usually takes longer to perform due 
to the complexity of the methodology. 
 
Mode of reporting 
The method of report transmission used must be agreed in advance with Laboratory Customer Services. 
Routine modes of reporting available are post or electronically (LER, DAIS).  
 
Post: 
Reports sent by post will be dispatched as soon as possible after completion of analysis. 
 
Fax: 
This reporting method is being phased out. Where this method is in use sample results will be faxed as 
soon as possible after completion of analysis.  
To ensure the confidentiality of the information transmitted, faxing of reports will only occur if the laboratory 
has been provided with a written and agreed secure fax number.  
 
 
Electronic Reporting 
 
Drugs Aids Information System (DAIS): HSE Addiction Service defined user’s access laboratory results via 
DAIS. This is completed once the laboratory authorises the samples. 
 
Laboratory Electronic Reporting (LER): The LER is a web-based system developed for NDTC customers 
which allows authorised users to access results electronically. Sample results are available in the system 
as soon as the analysis is complete.  
 
Verbal reporting:  
Verbal reporting can only be accommodated in the case of an emergency.
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Uncertainty of Measurement 
 
When interpreting laboratory reports, consideration should always be given to the Uncertainty of 
Measurement (UOM) associated with the test result, because no measurement is absolutely exact.  
When a   quantity is measured, the outcome depends on the measuring system, e.g. test procedure, 
environmental conditions, volumetric effects, reference values, sampling matrix, operator etc. Therefore all 
measurements are subject to uncertainty and this should be taken into account in the interpretation of 
laboratory results. This can have a bearing on immunoassay test results which are close to their cut-off 
point and therefore within the range of measurement uncertainty for the test cut-off. Clinical consideration 
and judgement should be applied to any immunoassay test result. Repeat testing or confirmatory analysis 
may be requested if required. The tests reported are qualitative with the exception of Alcohol which is 
quantitative. 
 
Uncertainty of Measurement for each test (see figures in brackets below). 
URINE TESTS 
OPIATE(+/-16.4%); 6-AMOR (+/-16.0%); BENZ(+/-14.5%); EDDP(+/-14.2%); CANN (+/-18.2%); AMPH (+/-
17.5%);COCA (+/-13.3%); ALCO (+/-12.9%); ETG (+/-17.3%); BUP(+/-16.3); pH (+/-11.8%). 
ORAL FLUID TESTS 
OPIATE(+/-20.0%); 6-AMOR (+/-21.0%); BENZ (+/-18.4%); CANN (+/-23.6%); AMPH (+/-24.8%); COCA (+/-16.8%), 
METH (+/-24.4%); METHAMPH (+/-22.6%). 
 
Quality Control and Quality Assurance 
 
To ensure the highest confidence in test results, the laboratory adheres to strict quality control (QC) and 
quality assurance (QA) standards. (Approx. 3% of all samples run are quality controls).  
 
In order to assess performance, the laboratory is involved in two external Quality Assurance schemes, the 
United Kingdom National External Quality Assessment Scheme (UKNEQAS) and the Irish External Quality 
Assessment Scheme (IEQAS). 
          
Viewing of quality control data, proficiency testing data, and testing procedures will be accommodated on 
request by arrangement with the laboratory.
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10 
Accreditation 
 
Our laboratory is accredited by the Irish National Accreditation Board (INAB) to ISO/IEC17025. ISO/IEC 
17025 is the main standard used by testing and calibration laboratories. 
 
The ISO/IEC 17025 standard is a quality system aimed at improving the ability to consistently produce valid 
results. The two main aspects of ISO/IEC 17025 Accreditation are Management and Technical 
Requirements. Management requirements are primarily related to the operation and effectiveness of the 
quality management system within the laboratory, while technical requirements address the competence of 
staff, methodology and test/calibration equipment.  
 
In order to maintain this high standard, our laboratory is assessed annually by a team of Irish and 
international external auditors. 
 
In 2013 and 2014 respectively we extended the scope of our accreditation to include Zopiclone 
confirmatory analysis in Urine and Buprenorphine by immunoassay. 
The scope of our accreditation can be viewed at www.inab.ie/pdf/169T.pdf 
 
 
Membership and Representation 
 
To ensure best practice and to keep up to date with the latest developments and trends in drug misuse, 
laboratory staff have professional membership and attend meeting of various international societies, 
these include:- 
ACBI – Association of Clinical Biochemists of Ireland 
TIAFT - The International Association Forensic Toxicologists 
SOFT- The Society of Forensic Toxicologists 
UK and Ireland Association of Forensic Toxicologist (UKIAFT) 
 
The laboratory is also represented at the Early Warning and Emerging Trends (EWET) committee of the 
National Advisory Committee on Drugs (NACD)
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Appendix 1 
 
Urine Immunoassay Cross Reactivity Tables        
 
Amphetamine/Ecstasy Assay (cut – off 1000ng/mL)* Drugs producing positive results 
Amphetamine 
Methamphetamine 
 
N-Methylbenzodioxazolylbutanamine 
(MBDB)  
3,4-Methylenedioxyamphetamine (MDA)  
 
3,4-Methylenedioxyethylamphetamine 
(MDEA)  
3,4-Methylenedioxymethamphetamine 
(MDMA) 
[This list is not exhaustive] – Please contact the laboratory if confirmation of a positive result is required 
* We have found that CEDIA® Amphetamine/Ecstasy assay may cross-react with other compounds particularly  
new psychoactive substances (‘Headshop’ Drugs/Bath Salts/Legal Highs). If you have any queries about  
an amphetamine positive result please contact the laboratory. Confirmatory analysis can be carried out on request. 
 
Opiate Class  (cut-off conc.300 ng/ml) Drugs producing positive results 
6-Monoacetylmorphine  
Diacetylmorphine  
Hydrocodone  
Hydromorphone  
Morphine  
 
Morphine-3-Glucuronide  
Morphine-6-Glucuronide  
Morphine Sulfate  
Nalorphine HCl  
Naloxone 
Naltrexone HCl  
Oxycodone  
Oxymorphone  
Pholcodine  
Thebaine 
[This list is not exhaustive] – Please contact the laboratory if confirmation of a positive result is required 
6-Acetylmorphine (10mg/dL) Drugs producing positive results 
6-Acetylmorphine  
[This list is not exhaustive] – Please contact the laboratory if confirmation of a positive result is required. 
 
Cannabis  (cut-off conc.50 ng/ml) Drugs producing positive results 
11-Nor- -9-THC-COOH  
11-Nor  8-THC-COOH  
 9-THC (Dronabinol)  
 11-Hydroxy-- 9-THC  
1- -9-THC-Glucuronide  
8-OH- -9-THC  
 
8 ,11-di-OH- -9-THC  
Cannabinol 
 
[This list is not exhaustive] – Please contact the laboratory if confirmation of a positive result is required 
 
Cocaine (cut-off conc. 300 ng/ml) Drugs producing positive results 
Benzoylecgonine  
Cocaethylene 
 
Cocaine 
[This list is not exhaustive] – Please contact the laboratory if confirmation of a positive result is required 
Ethyl Alcohol (mg/dL) Drugs producing positive results 
Ethanol  
n-Propanol  
[This list is not exhaustive] – Please contact the laboratory if confirmation of a positive result is required 
EDDP (cut-off conc. 100ng/mL) Drugs producing positive results 
2-Ethylidin-1,5-dimethyl-3,3-diphenylpyrrolidin (EDDP)  
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Oral Fluid Immunoassay Cross Reactivity 
 
We have limited information on cross-reactivity for Oral Fluid tests. Triazolam (Halcion) causes  
false positive results for 6-Acetylmorphine (6-AM) oral fluid test in patients who are prescribed this drug. 
Patients on Halcion are therefore unsuitable for oral fluid testing. Urine testing should be used for these 
patients. 
 
Appendix 2 
 
Interpretation of Benzodiazepine Identifications 
 
The routine immunoassay screening method for benzodiazepines is unable to distinguish between 
metabolites, therefore urinary benzodiazepine identifications are carried out where required using more 
sophisticated techniques (LC-MS and GC-MS) which can specifically target and unambiguously identify the 
drug or metabolite present.  
 
Benzodiazepines can be short-acting or long acting and depending on the drug taken they can persist for 
an extended time in the urine of habitual users even after all use has ceased. A further complication is that 
the metabolic pathways of benzodiazepines can often result in common metabolites (the most significant 
being Oxazepam) and this means that in many cases it may not be possible to determine the parent drug. 
Therefore it can be difficult to unambiguously identify which parent drug(s) was originally consumed. 
 
See Table 4 below. 
 
Many factors such as how much fluid has been consumed prior to giving the sample, the time since the 
drug was taken, the physical condition and metabolism of the patient etc. may influence the dilution of a 
urine sample and therefore the drug level present. Therefore drug levels in urine may be subject to large 
fluctuations. If urine is dilute, drug levels will be lowered. Consequently urinary levels should be interpreted 
with extreme caution. There is no direct correlation between urine drug levels and blood drug levels. 
 
Table 4: Benzodiazepine and Metabolites
Parent Drug Target Drug/Metabolite(s) Tested Parent  
Alprazolam hydroxyalprazolam, Alprazolam Present 
Bromazepam Bromazepam Present 
Chlordiazepoxide Chlordiazepoxide, Nordiazepam, Oxazepam, 
demoxepam 
Trace 
Clobazam Clobazam Trace 
Clonazepam Clonazepam, 7-aminoclonazepam Present 
Diazepam  Diazepam,Nordiazepam,Oxazepam,Temazepam Trace  
Estazolam Estazolam Trace 
Flunitrazepam Flunitrazepam, 7-Aminoflunitrazepam Not usually detected 
Flurazepam 2-Hydroxyethylflurazepam Trace 
Lorazepam Lorazepam glucuronide Present after hydrolysis 
Midazolam Midazolam Trace 
Nitrazepam Nitrazepam Trace 
Oxazepam Oxazepam,  Oxazepam glucuronide Present after hydrolysis 
Prazepam Oxazepam Not usually detected 
Temazepam Temazepam, Oxazepam Present 
Triazolam Triazolam, a-hydroxytriazolam Trace 
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Appendix 3 
Interpretation of Opiate Identifications 
 
Heroin is metabolised in the body, firstly to 6-acetylmorphine (6-AM) and then to 
Morphine.  
 
 
HEROIN  → 6 Acetyl Morphine (6-AM)  → Morphine 
 
 
The presence of 6-AM proves the use of Heroin. However, 6-AM has a short half-
life of approx. 24 hours in urine after last use, and therefore Morphine is the most 
commonly detected metabolite in Heroin abuse, due to its longer window of detection.  
 
Morphine in urine can also result from the metabolism of Codeine, which is included 
in many ‘over the counter’ painkillers. 
 
 
CODEINE → Morphine 
 
 
To add to the complexity, Acetylcodeine is an impurity often detected in Heroin. 
Acetylmorphine also metabolises to Codeine. 
 
 
HEROIN containing impurity Acetylcodeine → Codeine 
and  
HEROIN → 6 Acetyl Morphine (6-AM) → Morphine 
 
 
Because of these similar metabolic pathways, it can be difficult to distinguish 
between the use of Heroin, Morphine or Codeine, or the use of a combination of 
more than one of these, because both Morphine and Codeine may be present after 
Heroin use, Morphine use, or after Codeine use. 
 
The routine immunoassay screening method for opiates is targeted to detect 
Morphine, Codeine and Dihydrocodeine (or their metabolites) but it cannot 
distinguish between them.  
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Procedure for Opiate Identification: 
A positive opiate result by immunoassay will be obtained if any one, or a 
combination of the above, is present above the cut-off concentration of 
300ng/ml. 
 
In order to identify which opiate is present in a sample, further testing is required.  
 
Firstly, a 6-Acetylmorphine (6-AM) test is carried out and if positive, Heroin use is 
strongly indicated. If negative, further confirmatory testing must be performed. 
Because of the common metabolites, it may not always be possible to 
unambiguously differentiate between Heroin, Morphine and Codeine use (even 
using sophisticated confirmatory analysis techniques). See Table 5 below. 
 
 
Table 5:   Interpretation of Opiate ID results 
 
Immunoassay 
Result 
Result 
Confirmatory  analysis 
Interpretation 
 
6-AM n/a Heroin misuse 
Opiate Morphine Use of  Morphine or Heroin or 
Codeine or a combination of these 
Opiate Codeine Confirmation  of 
Codeine use 
Opiate Morphine and Codeine Use of  Morphine or Heroin or 
Codeine or a combination of these 
Opiate Dihydrocodeine Confirmation of 
Dihydrocodeine use 
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Appendix 4 
 
‘Legal highs’, ‘Head Shop’ products, New Psychoactive 
substances 
The terms ‘Legal highs’, ‘Head Shop products’ or  ‘New Psychoactive Substances’ refer to a 
number of new drugs with stimulant or psychoactive effects which had not been encountered 
as drugs of abuse or recreational drugs until recent years. Initially these were sold as ‘legal’ 
highs in so-called ‘Head Shops’ in Ireland and via the internet.  
Various legislative changes were enacted in Ireland to deal with the misuse of these 
substances. In 2009, 1-benzylpiperazine (BZP) was declared a controlled drug by the Irish 
government under the Misuse of Drugs Act 1977. In May 2010, the Irish Government made 
an order declaring a number of substances, including Synthetic Cannabinoids, 
Benzylpiperazine, Piperazine derivatives, Mephedrone, Methylone, Methedrone, Butylone, 
Flephedrone, and MDPV, GBL and 1,4 BD to become controlled drugs under the Misuse of 
Drugs Act 1977, with immediate effect.  
The Criminal Justice (Psychoactive Substances) Act 2010 came into effect on Monday 23
rd
 
August 2010 making it an offence, punishable by up to five years imprisonment, to sell or 
supply for human consumption, substances having psychoactive effects which are not 
specifically proscribed under the Misuse of Drugs Acts. In November 2011 the Misuse of 
Drugs (Amendment) Regulations 2011 was enacted. This further greatly extended the range 
of banned substances. Further substances were controlled by S.I. No. 323/2014 - Misuse of 
Drugs (Amendment) Regulations 2014. 
Unfortunately the controls put in place have not eliminated the use of these substances and 
they are still in use in the illicit drug market. In 2013, new psychoactive substances continue 
to be reported at a rate of around one a week to the EMCDDA early warning and risk 
assessment mechanism for responding to the emergence of new psychoactive substances.  
The Laboratory of the HSE-NDTC is currently testing in excess of 500 samples annually for 
New Psychoactive Substances (on request only). The profile of drugs detected over the last 
5 years has constantly changed. We endeavor to provide analysis for these substances as 
required and as reference standards become available. The panel of drugs screened will 
change as required to include more recent variants in the compounds tested. 
The most prevalent New Psychoactive Substances detected by the Laboratory of the HSE- 
NDTC in 2014/2015 were PVP, Pentedrone, 4-MEC, 5- APB and MDPBP. Polydrug use is 
evident in the samples tested.  
The parent drug is looked for in these analyses, as little is known about the metabolism of 
these drugs and in general, drug standards of the metabolites are not yet commercially 
available. There may be metabolites of these compounds that are present in higher 
concentrations than the parent in the urine and present for a longer time than the metabolite.    
It is not known how long any of these compounds are present in the urine. 
For the latest information on these products and the legislation relating to them, refer to 
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www.drugs.ie and the Irish Legislation website http://www.irishstatutebook.ie 
In March 2015 an update on new psychoactive substances in Europe was published from 
the EU Early Warning System. It stated that the large number of seizures of synthetic 
cathinones reflects the demand for stimulants in Europe, with many of them used as 
replacements for MDMA, amphetamine and cocaine. During 2014 some 31 synthetic 
cathinones were reported for the first time. This brings the total number of cathinones to 77, 
making them the second largest group of substances monitored by the EMCDDA. Between 
2008 and 2013 there has been a 60-fold increase in the number of seizures of synthetic 
cathinones. 
http://www.emcdda.europa.eu/publications/2015/new-psychoactive-substances 
 
Another recent EMCDDA publication was issued on the subject of injecting cathinones. 
http://www.emcdda.europa.eu/topics/pods/synthetic-cathinones-injection 
Another recent publication of relevance is “Guidance on the Clinical Management of Acute 
and Chronic Harms of Club Drugs and Novel Psychoactive Substances”; Abdulrahim D & 
Bowden-Jones O, on behalf of the NEPTUNE Expert Group. Novel Psychoactive Treatment 
UK Network (NEPTUNE). London, 2015. 
http://neptune-clinical-guidance.co.uk/ 
In June 2011 a report was published by the National Advisory Committee on Drugs: “An 
Overview of New Psychoactive Substances and the Outlets Supplying Them”. 
http://www.nacda.ie/index.php/publications/38-an-overview-of-new-psychoactive-
substances-and-the-outlets-supplying-them.html 
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